 | • レポートコード：GIR-107A12266 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、肢端紅痛症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。肢端紅痛症治療の種類別市場規模（治療薬、治療）、用途別市場規模（原発性肢端紅痛症、続発性肢端紅痛症）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・肢端紅痛症治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Teva Pharmaceutical Industries Ltd、Biogen、Pfizer Inc、Akorn、Novartis AG、Galderma SA、Acorda Therapeutics, Inc、AbbVie、Amneal Pharmaceuticals LLC、Xenon Pharmaceuticals Inc、Ligand Pharmaceuticals Incorporated、Zydus Cadila、ANI Pharmaceuticals, Inc、Lupin Limited、Bausch Health、Indoco Remedies Ltd ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：治療薬、治療 ・用途別分析2016年-2026年：原発性肢端紅痛症、続発性肢端紅痛症 ・肢端紅痛症治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・肢端紅痛症治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・肢端紅痛症治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・肢端紅痛症治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・肢端紅痛症治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Erythromelalgia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Erythromelalgia Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Erythromelalgia Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Erythromelalgia Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Drugs
Therapy
Market segment by Application, can be divided into
Primary Erythromelalgia
Secondary Erythromelalgia
Market segment by players, this report covers
Teva Pharmaceutical Industries Ltd
Biogen
Pfizer Inc
Akorn
Novartis AG
Galderma SA
Acorda Therapeutics, Inc
AbbVie
Amneal Pharmaceuticals LLC
Xenon Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated
Zydus Cadila
ANI Pharmaceuticals, Inc
Lupin Limited
Bausch Health
Indoco Remedies Ltd
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Erythromelalgia Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Erythromelalgia Treatment, with revenue, gross margin and global market share of Erythromelalgia Treatment from 2019 to 2021.
Chapter 3, the Erythromelalgia Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Erythromelalgia Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Erythromelalgia Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Erythromelalgia Treatment
1.2 Classification of Erythromelalgia Treatment by Type
1.2.1 Overview: Global Erythromelalgia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Erythromelalgia Treatment Revenue Market Share by Type in 2020
1.2.3 Drugs
1.2.4 Therapy
1.3 Global Erythromelalgia Treatment Market by Application
1.3.1 Overview: Global Erythromelalgia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Primary Erythromelalgia
1.3.3 Secondary Erythromelalgia
1.4 Global Erythromelalgia Treatment Market Size & Forecast
1.5 Global Erythromelalgia Treatment Market Size and Forecast by Region
1.5.1 Global Erythromelalgia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Erythromelalgia Treatment Market Size by Region, (2016-2021)
1.5.3 North America Erythromelalgia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Erythromelalgia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Erythromelalgia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Erythromelalgia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Erythromelalgia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Erythromelalgia Treatment Market Drivers
1.6.2 Erythromelalgia Treatment Market Restraints
1.6.3 Erythromelalgia Treatment Trends Analysis
2 Company Profiles
2.1 Teva Pharmaceutical Industries Ltd
2.1.1 Teva Pharmaceutical Industries Ltd Details
2.1.2 Teva Pharmaceutical Industries Ltd Major Business
2.1.3 Teva Pharmaceutical Industries Ltd Erythromelalgia Treatment Product and Solutions
2.1.4 Teva Pharmaceutical Industries Ltd Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.2 Biogen
2.2.1 Biogen Details
2.2.2 Biogen Major Business
2.2.3 Biogen Erythromelalgia Treatment Product and Solutions
2.2.4 Biogen Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Biogen Recent Developments and Future Plans
2.3 Pfizer Inc
2.3.1 Pfizer Inc Details
2.3.2 Pfizer Inc Major Business
2.3.3 Pfizer Inc Erythromelalgia Treatment Product and Solutions
2.3.4 Pfizer Inc Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Pfizer Inc Recent Developments and Future Plans
2.4 Akorn
2.4.1 Akorn Details
2.4.2 Akorn Major Business
2.4.3 Akorn Erythromelalgia Treatment Product and Solutions
2.4.4 Akorn Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Akorn Recent Developments and Future Plans
2.5 Novartis AG
2.5.1 Novartis AG Details
2.5.2 Novartis AG Major Business
2.5.3 Novartis AG Erythromelalgia Treatment Product and Solutions
2.5.4 Novartis AG Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Novartis AG Recent Developments and Future Plans
2.6 Galderma SA
2.6.1 Galderma SA Details
2.6.2 Galderma SA Major Business
2.6.3 Galderma SA Erythromelalgia Treatment Product and Solutions
2.6.4 Galderma SA Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Galderma SA Recent Developments and Future Plans
2.7 Acorda Therapeutics, Inc
2.7.1 Acorda Therapeutics, Inc Details
2.7.2 Acorda Therapeutics, Inc Major Business
2.7.3 Acorda Therapeutics, Inc Erythromelalgia Treatment Product and Solutions
2.7.4 Acorda Therapeutics, Inc Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Acorda Therapeutics, Inc Recent Developments and Future Plans
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Erythromelalgia Treatment Product and Solutions
2.8.4 AbbVie Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 AbbVie Recent Developments and Future Plans
2.9 Amneal Pharmaceuticals LLC
2.9.1 Amneal Pharmaceuticals LLC Details
2.9.2 Amneal Pharmaceuticals LLC Major Business
2.9.3 Amneal Pharmaceuticals LLC Erythromelalgia Treatment Product and Solutions
2.9.4 Amneal Pharmaceuticals LLC Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Amneal Pharmaceuticals LLC Recent Developments and Future Plans
2.10 Xenon Pharmaceuticals Inc
2.10.1 Xenon Pharmaceuticals Inc Details
2.10.2 Xenon Pharmaceuticals Inc Major Business
2.10.3 Xenon Pharmaceuticals Inc Erythromelalgia Treatment Product and Solutions
2.10.4 Xenon Pharmaceuticals Inc Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Xenon Pharmaceuticals Inc Recent Developments and Future Plans
2.11 Ligand Pharmaceuticals Incorporated
2.11.1 Ligand Pharmaceuticals Incorporated Details
2.11.2 Ligand Pharmaceuticals Incorporated Major Business
2.11.3 Ligand Pharmaceuticals Incorporated Erythromelalgia Treatment Product and Solutions
2.11.4 Ligand Pharmaceuticals Incorporated Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Ligand Pharmaceuticals Incorporated Recent Developments and Future Plans
2.12 Zydus Cadila
2.12.1 Zydus Cadila Details
2.12.2 Zydus Cadila Major Business
2.12.3 Zydus Cadila Erythromelalgia Treatment Product and Solutions
2.12.4 Zydus Cadila Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Zydus Cadila Recent Developments and Future Plans
2.13 ANI Pharmaceuticals, Inc
2.13.1 ANI Pharmaceuticals, Inc Details
2.13.2 ANI Pharmaceuticals, Inc Major Business
2.13.3 ANI Pharmaceuticals, Inc Erythromelalgia Treatment Product and Solutions
2.13.4 ANI Pharmaceuticals, Inc Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 ANI Pharmaceuticals, Inc Recent Developments and Future Plans
2.14 Lupin Limited
2.14.1 Lupin Limited Details
2.14.2 Lupin Limited Major Business
2.14.3 Lupin Limited Erythromelalgia Treatment Product and Solutions
2.14.4 Lupin Limited Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Lupin Limited Recent Developments and Future Plans
2.15 Bausch Health
2.15.1 Bausch Health Details
2.15.2 Bausch Health Major Business
2.15.3 Bausch Health Erythromelalgia Treatment Product and Solutions
2.15.4 Bausch Health Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Bausch Health Recent Developments and Future Plans
2.16 Indoco Remedies Ltd
2.16.1 Indoco Remedies Ltd Details
2.16.2 Indoco Remedies Ltd Major Business
2.16.3 Indoco Remedies Ltd Erythromelalgia Treatment Product and Solutions
2.16.4 Indoco Remedies Ltd Erythromelalgia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Indoco Remedies Ltd Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Erythromelalgia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Erythromelalgia Treatment Players Market Share
3.2.2 Top 10 Erythromelalgia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Erythromelalgia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Erythromelalgia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Erythromelalgia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Erythromelalgia Treatment Revenue Market Share by Application (2016-2021)
5.2 Erythromelalgia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Erythromelalgia Treatment Revenue by Type (2016-2026)
6.2 North America Erythromelalgia Treatment Revenue by Application (2016-2026)
6.3 North America Erythromelalgia Treatment Market Size by Country
6.3.1 North America Erythromelalgia Treatment Revenue by Country (2016-2026)
6.3.2 United States Erythromelalgia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Erythromelalgia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Erythromelalgia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Erythromelalgia Treatment Revenue by Type (2016-2026)
7.2 Europe Erythromelalgia Treatment Revenue by Application (2016-2026)
7.3 Europe Erythromelalgia Treatment Market Size by Country
7.3.1 Europe Erythromelalgia Treatment Revenue by Country (2016-2026)
7.3.2 Germany Erythromelalgia Treatment Market Size and Forecast (2016-2026)
7.3.3 France Erythromelalgia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Erythromelalgia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Erythromelalgia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Erythromelalgia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Erythromelalgia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Erythromelalgia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Erythromelalgia Treatment Market Size by Region
8.3.1 Asia-Pacific Erythromelalgia Treatment Revenue by Region (2016-2026)
8.3.2 China Erythromelalgia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Erythromelalgia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Erythromelalgia Treatment Market Size and Forecast (2016-2026)
8.3.5 India Erythromelalgia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Erythromelalgia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Erythromelalgia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Erythromelalgia Treatment Revenue by Type (2016-2026)
9.2 South America Erythromelalgia Treatment Revenue by Application (2016-2026)
9.3 South America Erythromelalgia Treatment Market Size by Country
9.3.1 South America Erythromelalgia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Erythromelalgia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Erythromelalgia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Erythromelalgia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Erythromelalgia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Erythromelalgia Treatment Market Size by Country
10.3.1 Middle East & Africa Erythromelalgia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Erythromelalgia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Erythromelalgia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Erythromelalgia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Erythromelalgia Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Erythromelalgia Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Erythromelalgia Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Erythromelalgia Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Erythromelalgia Treatment Revenue Market Share by Region (2021-2026)
Table 6. Teva Pharmaceutical Industries Ltd Corporate Information, Head Office, and Major Competitors
Table 7. Teva Pharmaceutical Industries Ltd Major Business
Table 8. Teva Pharmaceutical Industries Ltd Erythromelalgia Treatment Product and Solutions
Table 9. Teva Pharmaceutical Industries Ltd Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Biogen Corporate Information, Head Office, and Major Competitors
Table 11. Biogen Major Business
Table 12. Biogen Erythromelalgia Treatment Product and Solutions
Table 13. Biogen Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 15. Pfizer Inc Major Business
Table 16. Pfizer Inc Erythromelalgia Treatment Product and Solutions
Table 17. Pfizer Inc Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Akorn Corporate Information, Head Office, and Major Competitors
Table 19. Akorn Major Business
Table 20. Akorn Erythromelalgia Treatment Product and Solutions
Table 21. Akorn Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 23. Novartis AG Major Business
Table 24. Novartis AG Erythromelalgia Treatment Product and Solutions
Table 25. Novartis AG Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Galderma SA Corporate Information, Head Office, and Major Competitors
Table 27. Galderma SA Major Business
Table 28. Galderma SA Erythromelalgia Treatment Product and Solutions
Table 29. Galderma SA Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Acorda Therapeutics, Inc Corporate Information, Head Office, and Major Competitors
Table 31. Acorda Therapeutics, Inc Major Business
Table 32. Acorda Therapeutics, Inc Erythromelalgia Treatment Product and Solutions
Table 33. Acorda Therapeutics, Inc Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. AbbVie Corporate Information, Head Office, and Major Competitors
Table 35. AbbVie Major Business
Table 36. AbbVie Erythromelalgia Treatment Product and Solutions
Table 37. AbbVie Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Amneal Pharmaceuticals LLC Corporate Information, Head Office, and Major Competitors
Table 39. Amneal Pharmaceuticals LLC Major Business
Table 40. Amneal Pharmaceuticals LLC Erythromelalgia Treatment Product and Solutions
Table 41. Amneal Pharmaceuticals LLC Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Xenon Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 43. Xenon Pharmaceuticals Inc Major Business
Table 44. Xenon Pharmaceuticals Inc Erythromelalgia Treatment Product and Solutions
Table 45. Xenon Pharmaceuticals Inc Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Ligand Pharmaceuticals Incorporated Corporate Information, Head Office, and Major Competitors
Table 47. Ligand Pharmaceuticals Incorporated Major Business
Table 48. Ligand Pharmaceuticals Incorporated Erythromelalgia Treatment Product and Solutions
Table 49. Ligand Pharmaceuticals Incorporated Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Zydus Cadila Corporate Information, Head Office, and Major Competitors
Table 51. Zydus Cadila Major Business
Table 52. Zydus Cadila Erythromelalgia Treatment Product and Solutions
Table 53. Zydus Cadila Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. ANI Pharmaceuticals, Inc Corporate Information, Head Office, and Major Competitors
Table 55. ANI Pharmaceuticals, Inc Major Business
Table 56. ANI Pharmaceuticals, Inc Erythromelalgia Treatment Product and Solutions
Table 57. ANI Pharmaceuticals, Inc Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Lupin Limited Corporate Information, Head Office, and Major Competitors
Table 59. Lupin Limited Major Business
Table 60. Lupin Limited Erythromelalgia Treatment Product and Solutions
Table 61. Lupin Limited Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 63. Bausch Health Major Business
Table 64. Bausch Health Erythromelalgia Treatment Product and Solutions
Table 65. Bausch Health Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Indoco Remedies Ltd Corporate Information, Head Office, and Major Competitors
Table 67. Indoco Remedies Ltd Major Business
Table 68. Indoco Remedies Ltd Erythromelalgia Treatment Product and Solutions
Table 69. Indoco Remedies Ltd Erythromelalgia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Global Erythromelalgia Treatment Revenue (USD Million) by Players (2019-2021)
Table 71. Global Erythromelalgia Treatment Revenue Share by Players (2019-2021)
Table 72. Breakdown of Erythromelalgia Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 73. Erythromelalgia Treatment Players Head Office, Products and Services Provided
Table 74. Erythromelalgia Treatment Mergers & Acquisitions in the Past Five Years
Table 75. Erythromelalgia Treatment New Entrants and Expansion Plans
Table 76. Global Erythromelalgia Treatment Revenue (USD Million) by Type (2016-2021)
Table 77. Global Erythromelalgia Treatment Revenue Share by Type (2016-2021)
Table 78. Global Erythromelalgia Treatment Revenue Forecast by Type (2021-2026)
Table 79. Global Erythromelalgia Treatment Revenue by Application (2016-2021)
Table 80. Global Erythromelalgia Treatment Revenue Forecast by Application (2021-2026)
Table 81. North America Erythromelalgia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 82. North America Erythromelalgia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 83. North America Erythromelalgia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 84. North America Erythromelalgia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 85. North America Erythromelalgia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 86. North America Erythromelalgia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 87. Europe Erythromelalgia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 88. Europe Erythromelalgia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 89. Europe Erythromelalgia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 90. Europe Erythromelalgia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 91. Europe Erythromelalgia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 92. Europe Erythromelalgia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 93. Asia-Pacific Erythromelalgia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 94. Asia-Pacific Erythromelalgia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 95. Asia-Pacific Erythromelalgia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 96. Asia-Pacific Erythromelalgia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 97. Asia-Pacific Erythromelalgia Treatment Revenue by Region (2016-2021) & (USD Million)
Table 98. Asia-Pacific Erythromelalgia Treatment Revenue by Region (2021-2026) & (USD Million)
Table 99. South America Erythromelalgia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 100. South America Erythromelalgia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 101. South America Erythromelalgia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 102. South America Erythromelalgia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 103. South America Erythromelalgia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 104. South America Erythromelalgia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 105. Middle East & Africa Erythromelalgia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 106. Middle East & Africa Erythromelalgia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 107. Middle East & Africa Erythromelalgia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 108. Middle East & Africa Erythromelalgia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 109. Middle East & Africa Erythromelalgia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 110. Middle East & Africa Erythromelalgia Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Erythromelalgia Treatment Picture
Figure 2. Global Erythromelalgia Treatment Revenue Market Share by Type in 2020
Figure 3. Drugs
Figure 4. Therapy
Figure 5. Erythromelalgia Treatment Revenue Market Share by Application in 2020
Figure 6. Primary Erythromelalgia Picture
Figure 7. Secondary Erythromelalgia Picture
Figure 8. Global Erythromelalgia Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 9. Global Erythromelalgia Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 10. Global Erythromelalgia Treatment Revenue Market Share by Region (2016-2026)
Figure 11. Global Erythromelalgia Treatment Revenue Market Share by Region in 2020
Figure 12. North America Erythromelalgia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 13. Europe Erythromelalgia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Asia-Pacific Erythromelalgia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. South America Erythromelalgia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Middle East and Africa Erythromelalgia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Erythromelalgia Treatment Market Drivers
Figure 18. Erythromelalgia Treatment Market Restraints
Figure 19. Erythromelalgia Treatment Market Trends
Figure 20. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Figure 21. Biogen Recent Developments and Future Plans
Figure 22. Pfizer Inc Recent Developments and Future Plans
Figure 23. Akorn Recent Developments and Future Plans
Figure 24. Novartis AG Recent Developments and Future Plans
Figure 25. Galderma SA Recent Developments and Future Plans
Figure 26. Acorda Therapeutics, Inc Recent Developments and Future Plans
Figure 27. AbbVie Recent Developments and Future Plans
Figure 28. Amneal Pharmaceuticals LLC Recent Developments and Future Plans
Figure 29. Xenon Pharmaceuticals Inc Recent Developments and Future Plans
Figure 30. Ligand Pharmaceuticals Incorporated Recent Developments and Future Plans
Figure 31. Zydus Cadila Recent Developments and Future Plans
Figure 32. ANI Pharmaceuticals, Inc Recent Developments and Future Plans
Figure 33. Lupin Limited Recent Developments and Future Plans
Figure 34. Bausch Health Recent Developments and Future Plans
Figure 35. Indoco Remedies Ltd Recent Developments and Future Plans
Figure 36. Global Erythromelalgia Treatment Revenue Share by Players in 2020
Figure 37. Erythromelalgia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 38. Global Top 3 Players Erythromelalgia Treatment Revenue Market Share in 2020
Figure 39. Global Top 10 Players Erythromelalgia Treatment Revenue Market Share in 2020
Figure 40. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 41. Global Erythromelalgia Treatment Revenue Share by Type in 2020
Figure 42. Global Erythromelalgia Treatment Market Share Forecast by Type (2021-2026)
Figure 43. Global Erythromelalgia Treatment Revenue Share by Application in 2020
Figure 44. Global Erythromelalgia Treatment Market Share Forecast by Application (2021-2026)
Figure 45. North America Erythromelalgia Treatment Sales Market Share by Type (2016-2026)
Figure 46. North America Erythromelalgia Treatment Sales Market Share by Application (2016-2026)
Figure 47. North America Erythromelalgia Treatment Revenue Market Share by Country (2016-2026)
Figure 48. United States Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Canada Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Mexico Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Europe Erythromelalgia Treatment Sales Market Share by Type (2016-2026)
Figure 52. Europe Erythromelalgia Treatment Sales Market Share by Application (2016-2026)
Figure 53. Europe Erythromelalgia Treatment Revenue Market Share by Country (2016-2026)
Figure 54. Germany Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. France Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. United Kingdom Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Russia Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Italy Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Asia-Pacific Erythromelalgia Treatment Sales Market Share by Type (2016-2026)
Figure 60. Asia-Pacific Erythromelalgia Treatment Sales Market Share by Application (2016-2026)
Figure 61. Asia-Pacific Erythromelalgia Treatment Revenue Market Share by Region (2016-2026)
Figure 62. China Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Japan Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South Korea Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. India Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Southeast Asia Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Australia Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South America Erythromelalgia Treatment Sales Market Share by Type (2016-2026)
Figure 69. South America Erythromelalgia Treatment Sales Market Share by Application (2016-2026)
Figure 70. South America Erythromelalgia Treatment Revenue Market Share by Country (2016-2026)
Figure 71. Brazil Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Argentina Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Middle East and Africa Erythromelalgia Treatment Sales Market Share by Type (2016-2026)
Figure 74. Middle East and Africa Erythromelalgia Treatment Sales Market Share by Application (2016-2026)
Figure 75. Middle East and Africa Erythromelalgia Treatment Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. UAE Erythromelalgia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Methodology
Figure 80. Research Process and Data Source
世界の神経性過食症治療市場 2021：企業別、地域別、種類・用途別 The Bulimia Nervosa Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…- 世界の多発性硬化症治療薬・治療市場 2021：企業別、地域別、種類・用途別 The Multiple Sclerosis Drugs Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…
- 世界の多汗症治療市場 2021：企業別、地域別、種類・用途別 The Hyperhidrosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界のダンピング症候群治療市場 2021：企業別、地域別、種類・用途別 The Dumping Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 世界の色素脱失障害治療市場 2021：企業別、地域別、種類・用途別 The Hypopigmentation Disorder Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…